Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.12 USD
-0.52 (-19.70%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $2.11 -0.01 (-0.47%) 6:32 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Cyclacel Pharmaceuticals, Inc. [CYCC]
Reports for Purchase
Showing records 41 - 60 ( 75 total )
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: Oral Fadraciclib Performing Well, CYC140 Progressing Through Phase 1
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1 Fadraciclib Oral Presentation - Efficacy and Oral Bioavailability
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: Trials Progressing Well Despite COVID-19, Cash Runway Through 2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Published Preclinical Data Elucidate Fadraciclib''s Mechanism of Action
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Clinical Trials Unimpeded By COVID-19 Thus Far, Funded Through 2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Data May Guide Development Path for a Potentially First-in-Class Therapy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage Update - Biotechnology Sector
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We View CYC065 Single Agent Activity as Meaningful Progress; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare Sector
Provider: Roth Capital Partners, Inc.
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Data Updates Could Drive Value in the Near-Term; Reit Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Cyclacel Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady Progress With Multiple Data Readouts in the Near Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A